Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice.

Lloyd SA, Morony SE, Ferguson VL, Simske SJ, Stodieck LS, Warmington KS, Livingston EW, Lacey DL, Kostenuik PJ, Bateman TA.

Bone. 2015 Dec;81:562-572. doi: 10.1016/j.bone.2015.08.021. Epub 2015 Aug 28.

PMID:
26318907
2.

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.

Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26.

PMID:
25259718
3.

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5.

PMID:
21733832
4.

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.

J Bone Miner Res. 2010 Dec;25(12):2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

5.

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.

Bone. 2009 Oct;45(4):669-76. doi: 10.1016/j.bone.2009.06.011. Epub 2009 Jun 17.

PMID:
19539794
6.

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.

Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ.

J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215.

7.

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.

J Bone Miner Res. 2009 Apr;24(4):578-88. doi: 10.1359/jbmr.081206.

8.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK.

J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112.

9.

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ.

J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109.

10.

Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.

Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D.

J Bone Miner Res. 2007 Oct;22(10):1534-47.

12.

Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation.

Chensue SW, Warmington KS, Allenspach EJ, Lu B, Gerard C, Kunkel SL, Lukacs NW.

J Immunol. 1999 Jul 1;163(1):165-73.

13.

Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen-elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses.

Warmington KS, Boring L, Ruth JH, Sonstein J, Hogaboam CM, Curtis JL, Kunkel SL, Charo IR, Chensue SW.

Am J Pathol. 1999 May;154(5):1407-16.

14.

Expression and participation of eotaxin during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granuloma formation.

Ruth JH, Lukacs NW, Warmington KS, Polak TJ, Burdick M, Kunkel SL, Strieter RM, Chensue SW.

J Immunol. 1998 Oct 15;161(8):4276-82.

16.

IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation.

Ruth JH, Bienkowski M, Warmington KS, Lincoln PM, Kunkel SL, Chensue SW.

J Immunol. 1996 Apr 1;156(7):2503-9.

PMID:
8786311
17.
18.

Monocyte chemotactic protein expression during schistosome egg granuloma formation. Sequence of production, localization, contribution, and regulation.

Chensue SW, Warmington KS, Lukacs NW, Lincoln PM, Burdick MD, Strieter RM, Kunkel SL.

Am J Pathol. 1995 Jan;146(1):130-8.

19.
20.

Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response.

Chensue SW, Bienkowski M, Eessalu TE, Warmington KS, Hershey SD, Lukacs NW, Kunkel SL.

J Immunol. 1993 Oct 1;151(7):3654-62.

PMID:
8376799
21.

Evolving T cell responses in murine schistosomiasis. Th2 cells mediate secondary granulomatous hypersensitivity and are regulated by CD8+ T cells in vivo.

Chensue SW, Warmington KS, Hershey SD, Terebuh PD, Othman M, Kunkel SL.

J Immunol. 1993 Aug 1;151(3):1391-400.

PMID:
8335935
22.
23.

Role of IL-4 and IFN-gamma in Schistosoma mansoni egg-induced hypersensitivity granuloma formation. Orchestration, relative contribution, and relationship to macrophage function.

Chensue SW, Terebuh PD, Warmington KS, Hershey SD, Evanoff HL, Kunkel SL, Higashi GI.

J Immunol. 1992 Feb 1;148(3):900-6.

PMID:
1309844

Supplemental Content

Loading ...
Support Center